Updated on 14 May 2013
Agilent Technologies launches AdvanceBio Peptide Mapping BioHPLC and Zorbax RRHD 300-HILIC columns
Singapore: Agilent Technologies has launched AdvanceBio Peptide Mapping BioHPLC and Zorbax RRHD 300-HILIC columns, designed to deliver exceptional performance for the separation, characterization and analysis of a wide range of proteins, monoclonal antibodies, peptides and additional biologics. Each of these columns enables users to achieve the highest-resolution results, faster than ever before.
"We are excited to introduce these valuable new columns to our pharmaceutical customers and other life science researchers seeking ever-greater analytical sensitivity and speed," said Ms Anne Jones, Agilent's vice president and general manager for the chemistries business. "These products are an example of our ongoing commitment to advancing accuracy and productivity in biochromatography."
The new AdvanceBio Peptide Mapping column can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity. It can produce exceptional analytical results two to three times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes.
Each batch of AdvanceBio mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps. All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.